Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
11.420
Zitationen
12
Autoren
2001
Jahr
Abstract
Trastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.
Ähnliche Arbeiten
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene
1987 · 11.670 Zit.
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 · 11.440 Zit.
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 · 9.372 Zit.
Cell Signaling by Receptor Tyrosine Kinases
2010 · 7.795 Zit.
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 · 7.172 Zit.
Autoren
Institutionen
- University of California, Los Angeles(US)
- UCLA Health(US)
- UCLA Medical Center(US)
- McGill University(CA)
- University of Washington(US)
- Olgahospital(DE)
- Krankenhaus vom Roten Kreuz(DE)
- Rush University Medical Center(US)
- Presbyterian St. Luke's Medical Center(US)
- Vall d'Hebron Hospital Universitari(ES)
- Memorial Sloan Kettering Cancer Center(US)